AKT1 and neoplasm: Studies have validated that the concurrent use of ATP-competitive inhibitors to target the AKT/mTOR pathway and HER2 inhibitors can induce apoptosis in tumor cells and result in tumor shrinkage, with these effects being sustained over time.